Spravato is the first and only approved monotherapy for adults with refractory major depressive disorder. Approval of ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

The original approval required that patients on Spravato also receive an oral antidepressant. Now, the FDA says the drug can ...